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Abstract Binding of TRIP8b to the cyclic nucleotide binding domain (CNBD) of mammalian
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels prevents their regulation by
cAMP. Since TRIP8b is expressed exclusively in the brain, we envisage that it can be used for
orthogonal control of HCN channels beyond the central nervous system. To this end, we have
identified by rational design a 40-aa long peptide (TRIP8bnano) that recapitulates affinity and gating
effects of TRIP8b in HCN isoforms (hHCN1, mHCN2, rbHCN4) and in the cardiac current If in rabbit
and mouse sinoatrial node cardiomyocytes. Guided by an NMR-derived structural model that
identifies the key molecular interactions between TRIP8bnano and the HCN CNBD, we further
designed a cell-penetrating peptide (TAT-TRIP8bnano) which successfully prevented b-adrenergic
activation of mouse If leaving the stimulation of the L-type calcium current (ICaL) unaffected.
TRIP8bnano represents a novel approach to selectively control HCN activation, which yields the
promise of a more targeted pharmacology compared to pore blockers.
DOI: https://doi.org/10.7554/eLife.35753.001
Introduction
Hyperpolarization-activated cyclic nucleotide-gated (HCN1-4) channels are the molecular correlate
of the If/Ih current, which plays a key role in controlling several higher order physiological functions,
including dendritic integration and intrinsic rhythmicity both in cardiac and neuronal cells
(Robinson and Siegelbaum, 2003). Unique among the voltage-gated ion channel superfamily, HCN
channels are modulated by the direct binding of cAMP to their cyclic nucleotide binding domain
(CNBD). Binding of the cyclic nucleotide increases the channel open probability upon
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hyperpolarization via conformational changes in the CNBD that are propagated to the pore through
the C-linker domain (DiFrancesco and Tortora, 1991; Wainger et al., 2001; Zagotta et al., 2003).
In addition to cAMP, HCN channels are regulated by TRIP8b, a brain-specific auxiliary (b) subunit,
which modulates two independent features of the channel, namely trafficking and gating
(Santoro et al., 2009; Zolles et al., 2009). For this dual regulation, TRIP8b binds HCN channels
through two distinct sites: via the tetratricopeptide repeat (TPR) domain, which interacts with the
last three amino acids (SNL) of HCN channels and regulates their trafficking; and via the TRIP8bcore
domain, which interacts with the CNBD and antagonizes the effect of cAMP on the voltage depen-
dency of the channel (Santoro et al., 2011; Han et al., 2011; Hu et al., 2013).
Here, we focus our attention on the specific action of TRIP8b in preventing cAMP regulation of
HCN channels. Given the brain-specific localization of TRIP8b, we posit that a TRIP8b-derived pep-
tide drug, able to reproduce the effect of the full length protein on HCN channel gating, can be
developed for orthogonal selective regulation of HCN in cells/tissues in which TRIP8b is not
expressed. cAMP-dependent modulation of HCN channels underlies distinct roles of cAMP in heart
rate regulation (DiFrancesco, 1993) and development of peripheral neuropathic pain (Emery et al.,
2012; Herrmann et al., 2017), which can be dissected by using a TRIP8b-based tool. In this regard,
peptide-based drugs (2–50 aa long) are emerging as a fascinating application area as they open new
therapeutic possibilities with an advantage over small molecules in terms of specificity and affinity
for the target (Fosgerau and Hoffmann, 2015; Henninot et al., 2018). To this end, we searched for
the minimal peptide that binds to the CNBD and recapitulates the gating effect of full length TRIP8b
in three HCN isoforms (HCN1, HCN2 and HCN4) and in the native If current. In previous studies, we
identified the core portion of TRIP8b (TRIP8bcore, 80 aa long) that interacts with the HCN CNBD and
prevents cAMP modulation in full length channels (Santoro et al., 2011; Hu et al.,
2013; Saponaro et al., 2014). A recent paper (Lyman et al., 2017) reported an even shorter bind-
ing sequence of TRIP8b (37 aa). However, this peptide, which was identified by progressive trunca-
tion of TRIP8bcore, failed to reproduce the binding affinity of the starting construct. Moreover,
evidence for activity of this peptide on HCN currents is lacking. In the present study, we adopted a
structure-driven rational design approach to engineer a 40-aa long peptide, TRIP8bnano, that effi-
ciently prevents cAMP regulation of HCN channels. The rational design of this peptide, based on
secondary structure predictions and on NMR data of TRIP8bcore, was supported by an NMR-based
3D model structure of the complex formed by the TRIP8bnano peptide and CNBD of the human
HCN2 channel isoform. This structural information identifies crucial interactions between the two
partners and explains both direct (Han et al., 2011; DeBerg et al., 2015; Bankston et al., 2017)
and indirect (allosteric) (Hu et al., 2013; Saponaro et al., 2014) modes of competition between
TRIP8b and cAMP for binding to the CNBD. The evidence that TRIP8bnano establishes all relevant
interactions with the CNBD is reflected by the finding that, contrary to shorter core sequences
(Lyman et al., 2017), it binds to the isolated CNBD with the same affinity as TRIP8bcore and acts
with even higher efficacy than TRIP8bcore in preventing cAMP modulation of full length HCN chan-
nels (Hu et al., 2013). In pacemaker myocytes of the sino-atrial node (SAN), TRIP8bnano equally pre-
vented cAMP stimulation of native f-channels leading to a 30% reduction in spontaneus firing rate.
To develop TRIP8bnano as a membrane permeable drug, we linked it with the positively charged
TAT sequence (Herce et al., 2014). TAT-TRIP8bnano was tested in SAN pacemaker myocytes where
its addition to the extracellular buffer prevented adrenergic stimulation of the If current leaving the
activation of the L-type calcium current (ICaL) unaffected. Our study opens the possibility of selective
in vivo control of the cAMP-dependent facilitation of HCN channel opening, by local supply of TAT-
TRIP8bnano peptide.
Results
We have previously shown that TRIP8bcore (residues 223–303 of mouse TRIP8b splice variant 1a4,
hereafter TRIP8b) interacts with two elements of the isolated CNBD protein fragment from HCN
channels (residues 521–672 of human HCN2, hereafter CNBD): the C-helix and the N-bundle loop, a
sequence connecting helix E’ of the C-linker with helix A of the CNBD (Saponaro et al., 2014). Bio-
chemical assays confirmed that each of these two elements, that is, the N-bundle loop and C-helix,
is necessary but not sufficient for binding (Saponaro et al., 2014).
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To understand the interaction in atomic detail, we used solution NMR spectroscopy to character-
ize the structural properties of the CNBD - TRIP8bcore complex. However, the NMR spectra of
TRIP8bcore showed very few signals. In order to improve the quality of the NMR spectra, we reduced
the length of the TRIP8b fragment by progressively removing residues at the N- and C-termini with
no predicted secondary structure. The truncated peptides were then tested for CNBD binding activ-
ity by isothermal titration calorimetry (ITC). We thus identified a 40-aa peptide (TRIP8bnano, compris-
ing residues 235–275 of TRIP8b, Figure 1A) with a binding KD of 1.5 ± 0.1 mM, a value similar to the
KD of 1.2 ± 0.1 mM obtained with TRIP8bcore (Figure 1B). TRIP8bnano was therefore employed for all
subsequent NMR experiments, resulting in a remarkable improvement in the spectral quality and
sample stability.
Structural characterization of TRIP8bnano bound to CNBD
The comparison of the 1H-15N HSQC spectra of TRIP8bnano with and without CNBD bound shows
that the peptide folds upon interaction with the CNBD. Thus, the 1H-15N HSQC spectrum of TRIP8b-
nano without CNBD shows a limited
1H resonance dispersion, characteristic of unstructured proteins
(Dyson and Wright, 2004), while a larger number of well-dispersed amide signals appear in the
spectrum of the CNBD-bound form (Figure 1C). Importantly, we were now able to assign the back-
bone chemical shift resonances of TRIP8bnano bound to the CNBD. The j and y dihedral angles
obtained from the NMR assignment indicate that the peptide displays two a-helices (stretch L238-
E250 named helix N and stretch T253-R269 named helix C) when bound to CNBD. The helices are sep-
arated by two amino acids; three and six residues at the N- and C- termini, respectively, are unstruc-
tured (Figure 1D).
Structural characterization of CNBD bound to TRIP8bnano
NMR-analysis of the CNBD fragment bound to TRIP8bnano revealed that the interaction with the
peptide does not affect the overall fold of the protein. Thus, the CNBD adopts the typical fold of
the cAMP-free state, in line with previous evidence that this is the form bound by TRIP8b
(Saponaro et al., 2014; DeBerg et al., 2015) More specifically, the secondary structure elements of
the cAMP-free CNBD are all conserved in the TRIP8bnano–bound CNBD (Figure 2). This finding gen-
erally agrees with a previous double electron-electron resonance (DEER) analysis of the CNBD -
TRIP8b interaction, which showed that TRIP8b binds to a conformation largely similar to the cAMP-
free state (DeBerg et al., 2015). Despite the overall agreement with the DEER study, the NMR data
also reveal a new and unexpected feature of TRIP8b binding to the CNBD. Indeed, our results show
that TRIP8bnano binding to the CNBD induces a well-defined secondary structure of the distal region
of the C-helix (Figure 2). This means that the distal region of the C-helix (residues 657–662), which is
unstructured in the free form of the CNBD (Saponaro et al., 2014; Lee and MacKinnon, 2017),
extends into a helical structure upon ligand binding irrespectively of whether the ligand is cAMP
(Puljung and Zagotta, 2013; Saponaro et al., 2014; Lee and MacKinnon, 2017) or TRIP8b (Fig-
ure 2). In contrast, and very differently from cAMP, which directly contacts the P-helix in the Phos-
phate Binding cassette (PBC) and causes its folding (Saponaro et al., 2014; Lee and MacKinnon,
2017), the NMR data show that TRIP8bnano binding to the CNBD does not induce P-helix formation
(Figure 2).
Modeling the CNBD - TRIP8bnano complex
Despite the significant improvement in sample stability and NMR spectra quality achieved upon
TRIP8bnano binding, we were still unable to assign the side chains of both proteins in the complex
and thus could not solve the solution structure of the complex by the canonical NMR procedure. We
therefore built a model (Figure 3) of the CNBD - TRIP8bnano complex by docking the two NMR-
derived structures described above using the Haddock program (a detailed description of how the
respective structures were generated is provided in Materials and methods and Figure 3—source
data 1).
In order to define the active residues (ambiguous interaction restraints) on the CNBD we used
the chemical shift perturbation values as described in Figure 3—figure supplement 1. For TRIP8b-
nano, we defined as active a stretch of residues, E239-E243, previously identified as critical for the inter-
action (Santoro et al., 2011). Output clusters of this first molecular docking calculation (settings can
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Figure 1. Functional and structural characterization of TRIP8bnano. (A) Primary sequence of TRIP8bnano. Amino acid
numbering refers to full length mouse TRIP8b (1a4). (B) Binding of TRIP8bcore and TRIP8bnano to purified His6-MBP-
CNBD measured by Isothermal titration calorimetry (ITC). Upper panel, heat changes (mcal/sec) during successive
injections of 8 mL of the corresponding TRIP8b peptide (200 mM) into the chamber containing His6-MBP-CNBD (20
Figure 1 continued on next page
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be found in Materials and methods) were further screened for TRIP8bnano orientations in agreement
with a previous DEER analysis, which placed TRIP8b residue A248 closer to the proximal portion and
TRIP8b residue A261 closer to the distal portion of the CNBD C-helix (DeBerg et al., 2015). Remark-
ably, in all clusters selected in this way, residues E264 or E265 in TRIP8b were found to interact with
residues K665 or K666 of the CNBD (Figure 3—figure supplement 2). This finding was notable,
because we previously identified K665/K666 as being critical for TRIP8b interaction in a biochemical
binding assay (Saponaro et al., 2014). We thus proceeded to individually mutate each of these four
positions, and test their effect on binding affinity through ITC. As expected, reverse charge muta-
tions K665E or K666E (CNBD) as well as E264K or E265K (TRIP8bnano) each strongly reduced the CNBD/
TRIP8bnano binding affinity (Figure 3—figure supplement 3).
Based on these observations, we performed a second molecular docking calculation, including
E264 and E265 as additional active residues for TRIP8bnano. This procedure resulted in the model
shown in Figure 3, which represents the top-ranking cluster for energetic and scoring function (Fig-
ure 3—source data 2) and was fully validated by mutagenesis analysis as described below. Scrutiny
of the model shows that TRIP8bnano binds to both the C-helix and the N-bundle loop (Figure 3A).
Binding to the C-helix is mainly guided by electrostatic interactions between the negative charges
on TRIP8bnano, and the positive charges on the CNBD (Figure 3A). As shown in Figure 3B, the
model highlights a double saline bridge (K665 and K666 of CNBD with E265 and E264 of TRIP8bnano) in
line with the ITC results described above (Figure 3—figure supplement 3). Of note, the contribu-
tion of residue R662 to the binding is also consistent with previous experiments showing residual
TRIP8b interaction in a CNBD deletion mutant ending at position 663 (Saponaro et al., 2014). Our
modeling data suggest that, upon folding of the distal portion of the C-helix, the side chains of resi-
dues R662 and K665 face to the inside when contacting cAMP, but face to the outside when binding
TRIP8b (Figure 3—figure supplement 4). This indicates that cAMP and TRIP8b directly compete for
the binding to the distal region of C-helix.
In addition to clarifying the role of residues in the distal portion of the CNBD C-helix, the model
also highlights a second important cluster of electrostatic interactions, with R650 in the proximal por-
tion of the CNBD C-helix contacting E240 and E241 in helix N of TRIP8bnano (Figure 3C). To confirm
the contribution of these residues, we reversed charges and tested each residue mutation for bind-
ing in ITC. The results in Figure 3—figure supplement 3 show that R650E caused a more than six-
fold reduction in binding affinity for TRIP8bnano, with smaller but significant effects seen also for
E240R and E241R.
A third important contact highlighted by the model is the interaction between N547 in the N-bun-
dle loop of the CNBD and D252 in the link between helix N and helix C of TRIP8bnano (Figure 3D).
We tested this potential interaction by disrupting the expected hydrogen bond between N547 and
the carboxyl group of the negative residue (D252) in TRIP8bnano. The asparagine in CNBD was
mutated into aspartate (N547D) to generate an electrostatic repulsion for D252, and the carboxyl
group in D252 of TRIP8bnano was removed by mutation into asparagine (D252N). As predicted, N547D
greatly reduced binding to TRIP8b in ITC assays (Figure 3—figure supplement 3), with a smaller
but significant effect observed also for D252N (Figure 3—figure supplement 3). These results
Figure 1 continued
mM). Lower panel, binding curve obtained from data displayed in the upper panel. The peaks were integrated,
normalized to TRIP8b peptide concentration, and plotted against the molar ratio (TRIP8b peptide/His6-MBP-
CNBD). Solid line represents a nonlinear least-squares fit to a single-site binding model, yielding, in the present
examples, a KD = 1.2 ± 0.1 mM for TRIP8bcore and KD = 1.4 ± 0.1 mM for TRIP8bnano. (C) Evidence for TRIP8bnano
folding upon CNBD binding based on the superimposition of the [1H, 15N] heteronuclear single quantum
coherence (HSQC) NMR spectrum of CNBD-free TRIP8bnano (black) and CNBD-bound TRIP8bnano (red). The latter
experiment was performed at the molar ratio ([CNBD]/[TRIP8bnano])=3. The backbone amide (HN) signals of the
residues of CNBD-bound TRIP8bnano are labelled in red. (D) (Top) Ribbon representation of the 10 lowest energy
conformers of TRIP8bnano bound to CNBD used for in silico modelling of CNBD-TRIP8bnano complex. The
unfolded regions at the N- and C-termini of the construct (residues 235–237 and 270–275) are omitted for clarity.
(Bottom) Chemical Shift Index (CSI, calculated using TALOS+) plotted as a function of the residue number of
TRIP8bnano bound to CNBD. Positive values represent helical propensity.
DOI: https://doi.org/10.7554/eLife.35753.002
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Figure 2. NMR structure of CNBD bound to TRIP8bnano. (A) (Top) comparison of secondary structure elements of
cAMP-free CNBD (Saponaro et al., 2014), cAMP-bound CNBD (Zagotta et al., 2003) and cAMP-free CNBD
bound to TRIP8bnano (this study). Secondary structure elements are indicated by arrows (b-strands) and cylinders
(a-helices) and labeled. The loop between b6 and b7 constitutes the Phosphate Binding Cassette (PBC). The
elements that fold upon binding of cAMP and TRIP8bnano are shown in red. (Bottom) Chemical Shift Index (CSI,
calculated using TALOS+) plotted as a function of the residue number of CNBD bound to TRIP8bnano. Positive
values represent helical propensity, while negative values represent strands. (B) Ribbon representation of the 10
lowest energy conformers of CNBD bound to TRIP8bnano used for in silico modeling of CNBD - TRIP8bnano
complex. Secondary structure elements are coloured in light gray and labeled. Loop regions are colored in dark
gray. The distal region of the C-helix (residues 657–662), which is unfolded in the free form of the CNBD
(Saponaro et al., 2014) and folds upon TRIP8bnano binding, is coloured in red. The unfolded regions at the N-
and C-termini of the construct (residues 521–532 and 663–672 respectively) are omitted for clarity.
DOI: https://doi.org/10.7554/eLife.35753.003
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Figure 3. Structural model of CNBD – TRIP8bnano complex. (A) Ribbon representation of the complex where CNBD is in gray and TRIP8bnano is in
orange. Helix N (N) and helix C (C) of TRIP8bnano are labeled. C-helix of CNBD (aC) is labeled, while N-bundle loop is colored in yellow. Positively
charged residues of C-helix CNBD (blue) and negatively charged residues of TRIP8bnano (red) involved in salt bridges are shown as sticks and labeled.
N547 of the N-bundle loop (yellow) and D252 of TRIP8bnano (orange) are shown as sticks and labeled. (B) Close view of K665 and K666 of CNBD that
interact, respectively, with E265 and E264 of TRIP8bnano. C-helix (aC) of CNBD, and Helix C (C) of TRIP8bnano are labeled. (C) Close view of R650 of CNBD
that is positioned between E240 and E241 of TRIP8bnano. C-helix (aC) of CNBD, and Helix N (N) of TRIP8bnano are labeled. (D) Close view of N547 of
N-bundle loop that forms a hydrogen bond (red dashed line) with D252 of TRIP8bnano. Helix E’ (aE’) and C-helix (aC) of CNBD, and Helix N (N) of
TRIP8bnano are labeled.
DOI: https://doi.org/10.7554/eLife.35753.004
The following source data and figure supplements are available for figure 3:
Source data 1. Acquisition parameters for NMR experiments performed on cAMP-free human HCN2 CNBD in complex with TRIP8bnano and vice-versa.
DOI: https://doi.org/10.7554/eLife.35753.011
Source data 2. Docking calculation.
DOI: https://doi.org/10.7554/eLife.35753.012
Figure supplement 1. CNBD residues involved in TRIP8bnano binding.
DOI: https://doi.org/10.7554/eLife.35753.005
Figure supplement 2. Representative families of clusters obtained from the first docking calculation.
Figure 3 continued on next page
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confirm and extend our previous finding that the N-bundle loop contributes in a substantial manner
to the binding of TRIP8b (Saponaro et al., 2014). To understand the mechanism for the allosteric
effect of TRIP8b on cAMP binding, which has been postulated on the basis of electrophysiological
and structural data (Hu et al., 2013; Saponaro et al., 2014), we further tested by ITC the affinity of
the N547D CNBD mutant for cAMP. Somewhat surprisingly, the affinity of the mutant is much lower
than that of the wt (N547D KD = 5.5 ± 0.4 mM (n = 3) vs. wt KD = 1.4 ± 0.1 mM (n = 3)). Moreover, we
measured a reduced sensitivity to cAMP also in patch clamp experiments where addition of 5 mM
cAMP caused a right shift in the V1/2 of the mutant HCN2 channel of only 5 mV while the wt channel
shifted by 12 mV (Figure 3—figure supplement 5). To exclude that the N547D mutation affects the
overall structure of the CNBD, we performed the NMR (1H-15N HSQC spectrum) analysis of the
N547D CNBD mutant. Our data show that the protein is appropriately folded (Figure 3—figure sup-
plement 6). In conclusion, since the N-bundle loop does not directly contact any of the residues of
the cAMP binding pocket, these findings underscore a previously unaddressed role of the N-bundle
loop in allosterically modulating cAMP binding to the CNBD (see Discussion).
TRIP8bnano as a tool for the direct regulation of native HCN currents
Next, we asked whether the relatively short TRIP8bnano could be used to block cAMP-dependent
modulation of HCN channels by delivering the peptide to full length channels. To this end, we dia-
lyzed TRIP8bnano into the cytosol of HEK 293 T cells transfected either with HCN1, HCN2, or HCN4
channels. The peptide was added (10 mM) in the recording pipette together with a non-saturating
concentration of cAMP (5 mM for HCN2, 1 mM for HCN4) expected to induce a ~ 10 mV rightward
shift in the half-activation potential (V1/2) of the channels (Figure 4). No cAMP was added in the case
of HCN1, because, in HEK 293 T cells, this isoform is already fully shifted to the right by the endoge-
nous cAMP and does not respond further (Figure 4—figure supplement 1). Indeed, it is possible to
induce a ~10 mV left shift in HCN1 V1/2 by introducing the mutation R549E that prevents cAMP bind-
ing to the CNBD (Figure 4—figure supplement 1).
Figure 4A–C show representative current traces recorded at four given voltages, in control
solution, cAMP, and cAMP +10 mM TRIP8bnano (HCN4 and HCN2) or +10 mM
TRIP8bnano only (HCN1) in the patch pipette. Already from a visual comparison of the most positive
voltage at which the current appears measurable, it is evident that TRIP8bnano counteracts the activ-
ating effect of cAMP on the voltage-dependent gating. In the case of HCN1, the effect of TRIP8b-
nano can be observed without added cAMP for the aforementioned reasons. Figure 4D–F show the
mean channel activation curves obtained from the above and other experiments. Fitting the Boltz-
mann equation to the data (solid and dashed lines of Figure 4D–F, see Materials and methods for
equation) yielded the half-activation potential values (V1/2) plotted in Figure 4G. The addition of
TRIP8bnano prevents the cAMP-induced right shift of about 13 mV in HCN4 (V1/2 = -102.8, –89.2,
 102.1 mV, for control, cAMP and cAMP + TRIP8bnano, respectively), and of about 11 mV in HCN2
(V1/2 = -93.7, –83.5,  94.5 mV, for control, cAMP and cAMP + TRIP8bnano, respectively). In HCN1,
TRIP8bnano induced a left shift in V1/2 of about 10 mV (from – 72.8 to  82 mV) which is comparable
to that induced by the R549E mutation (from  72.7 to  80.4 mV) (Figure 4—figure supplement 1).
Figure 4G also shows the result of a control experiment performed on HCN4 where 10 mM
TRIP8bnano was added to the extracellular medium (TRIP8bnano bath) in order to test if the peptide
was able to cross the cell membrane (current traces and activation curves not shown). The V1/2 value,
which is similar to that of cAMP alone ( 91.7 vs.  89.2 mV), confirmed that TRIP8bnano peptide
Figure 3 continued
DOI: https://doi.org/10.7554/eLife.35753.006
Figure supplement 3. Biochemical validation of CNBD – TRIP8bnano complex.
DOI: https://doi.org/10.7554/eLife.35753.007
Figure supplement 4. Different orientation of R662 and K665 in the cAMP-bound and TRIP8bnano-bound conformation of the CNBD.
DOI: https://doi.org/10.7554/eLife.35753.008
Figure supplement 5. Mutation N520D affects cAMP affinity in full-length HCN2 channel.
DOI: https://doi.org/10.7554/eLife.35753.009
Figure supplement 6. Structural characterization of N547D CNBD protein.
DOI: https://doi.org/10.7554/eLife.35753.010
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Figure 4. TRIP8bnano abolishes cAMP effect on HCN channel gating. (A-C) Representative whole-cell HCN4, HCN2 and HCN1 currents recorded, at the
indicated voltages, with control solution or with cAMP (1 mM for HCN4 and 5 mM for HCN2) or with cAMP + 10 mM TRIP8bnano in the patch pipette (for
HCN1, 10 mM TRIP8bnano only was added). (D-F) Mean activation curves measured from HCN4, HCN2 and HCN1 in control solution (open circles),
cAMP (filled circles), cAMP +TRIP8bnano, or TRIP8bnano only in the case of HCN1 (filled triangles). Solid and dashed lines indicate Boltzmann fitting to
the data (see Materials and methods). (G) Half activation potential (V1/2) values of HCN4 (blue), HCN2 (black) HCN1 (red) in control solution (open
circle), cAMP (filled circle) and cAMP +TRIP8bnano, or TRIP8bnano only in the case of HCN1 (filled triangle). HCN4, control =  102.8 ± 0.3 mV; HCN4 +1
mM cAMP =  89.2 ± 0.6 mV; HCN4 +1 mM cAMP +10 mM TRIP8bnano =  102.1 ± 0.6 mV, HCN4 +1 mM cAMP in the patch pipette +10 mM TRIP8bnano in
the bath solution =  91.7 ± 0.3 mV; HCN2, control =  93.7 ± 0.3 mV; HCN2 +5 mM cAMP =  83.5 ± 0.3 mV; HCN2 +5 mM cAMP +10 mM
TRIP8bnano =  94.5 ± 0.6 mV; HCN1, control =  72.8 ± 0.2 mV; HCN1 +10 mM TRIP8bnano =  82 ± 0.5 mV. Data are presented as mean ± SEM.
Number of cells (N)  11. There is no significant difference between the controls and the addition of TRIP8bnano with (HCN4, HCN2) or without (HCN1)
cAMP in the pipette. No significant difference was observed following the addition of TRIP8bnano in the bath. Statistical analysis performed with two-
way ANOVA, followed by post-hoc Tukey test (p<0.001).
DOI: https://doi.org/10.7554/eLife.35753.013
The following figure supplements are available for figure 4:
Figure supplement 1. Comparison of half activation potentials (V1/2) of HCN1 WT and HCN1 R549E mutant (Chen et al., 2001).
DOI: https://doi.org/10.7554/eLife.35753.014
Figure supplement 2. Voltage-dependency of activation time constant (ton) of HCN4 channels in control solution (open circles), 1 mM cAMP (filled
circles), 1 mM cAMP + 10 mM TRIP8bnano (filled triangles).
DOI: https://doi.org/10.7554/eLife.35753.015
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affects channel gating only if added to the intracellular solution presumably because it does not dif-
fuse through the cell membrane.
It is worth noting that TRIP8bnano prevents other related effects of cAMP activation in HCN chan-
nels, such as the acceleration of activation kinetics (Wainger et al., 2001) and, for HCN2 only, the
increase in maximal current (Chen et al., 2007; Hu et al., 2013). For example, the activation kinetics
(ton) of HCN4 measured at  120 mV was: control = 2 ± 0.2 s, 1 mM cAMP = 1.2 ± 0.1
s, 1 mM cAMP + 10 mM TRIP8bnano = 2 ± 0.3 s (Figure 4—figure supplement 2). Moreover,
Figure 4B clearly shows that TRIP8bnano fully prevented the increase in maximal current in HCN2.
Based on these results, we reckoned the peptide may be employed as a regulatory tool for native
If/Ih currents. As proof of principle, we tested whether TRIP8bnano can modulate the frequency of
action potential firing in SAN myocytes. In these cells, If is key contributor of the diastolic depolariza-
tion phase of the pacemaker action potential cycle. Moreover, the autonomic nervous system modu-
lates the frequency of action potential firing by changing intracellular cAMP levels, which in turn acts
on f-HCN channel open probability (DiFrancesco, 1993). We thus recorded the native If current in
acutely isolated rabbit SAN myocytes with and without 10 mM TRIP8bnano in the pipette solution
(Figure 5A). Figure 5B shows that the averaged If activation curve measured in presence of TRIP8b-
nano is significantly shifted to hyperpolarized voltages compared to the control. This indicates that
the peptide is displacing the binding of endogenous cAMP to native HCN channels. Moreover,
when the experiment was repeated in the presence of 1 mM cAMP, TRIP8bnano prevented the typical
cAMP-dependent potentiation of the native If current (Figure 5B). In light of these results, we tested
whether TRIP8bnano is also able to modulate cardiac automaticity by antagonizing basal cAMP. The
data in Figure 5C show that TRIP8bnano indeed significantly decreased the rate of action potential
firing in single SAN cells. Strikingly, the observed 30% decrease in action potential rate corresponds
to the effect induced by physiological concentrations of acetylcholine (DiFrancesco et al., 1989).
To conclusively prove that the inhibition of the native If current was specifically due to TRIP8bnano
rather than caused by the dilution of the cellular content following whole cell configuration, we cre-
ated a TAT version of TRIP8bnano (hereafter TAT-TRIP8bnano). Indeed, the TAT sequence allows the
entry of biomolecules into a cell via endocytosis and/or direct translocation across the plasma mem-
brane, thus leaving the cytosolic content unaltered (Guidotti et al., 2017).
We therefore tested whether both TRIP8bnano and TAT-TRIP8bnano were able to selectively inhibit
the b-adrenergic stimulation of If current, while leaving the potentiation of L-type Ca
2+ current (ICa,L)
unaltered. To this end, we recorded either the native If or ICa,L current from cardiomyocytes acutely
isolated from mouse sinoatrial node (SAN) in the presence and in the absence of 10 mM TRIP8bnano
or TAT-TRIP8bnano, before and after stimulation with 100 nM isoproterenol (ISO), a b-adrenergic
receptor agonist (Figure 6). Strikingly, TRIP8bnano prevented the isoproterenol-induced increase of If
current density, both when the peptide was added in the recording pipette solution (Figure 6A and
B), and when it was used in the TAT version added to the bath (Figure 6A and C). The specificity of
TRIP8bnano for If current was confirmed by the absent inhibition of basal ICa,L (Figure 6D). In addi-
tion, we failed to record a significant difference in the isoproterenol-stimulated increase of the ICaL
current density between the control condition and 10 mM TRIP8bnano (Figure 6E) or TAT-TRIP8bnano
(Figure 6F) conditions. To test whether the TAT-TRIP8bnano effect described above was exclusively
due to TRIP8bnano peptide, we repeated the experiments with a scrambled version of the peptide
(TAT- (SCRAMBLED) TRIP8bnano) to exclude that the effect could be due to the TAT sequence (Fig-
ure 6—figure supplement 1). We failed to observe a significant reduction in the responsiveness of If
to isoproterenol in the presence of TAT- (SCRAMBLED) TRIP8bnano confirming that prevention of
cAMP induced f- current stimulation was specific of the TRIP8bnano sequence.
Discussion
TRIP8b-CNBD complex
In this study, we have identified the minimal binding peptide that reproduces the effects of TRIP8b
on HCN channel gating. The peptide is 40 aa long and binds the HCN CNBD with high affinity
(KD = 1.4 mM). By solving the NMR structures of TRIP8bnano and HCN CNBD in the bound form, we
generated a structural model of their complex. The model provides detailed information on this pro-
tein-protein interaction at the atomic level with implications on their physiological function. The data
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show that the minimal binding unit of TRIP8b, TRIP8bnano, folds in two helices upon binding and sug-
gest that this region is intrinsically disordered when it is not bound. The model structurally validates
previous indirect evidence, which suggested that TRIP8b binds to two discrete elements of the
CNBD: the N-bundle loop and the C-helix (Saponaro et al., 2014). The complex forms by electro-
static interactions, which are spread throughout the contact surface. As a consequence of the inter-
action with TRIP8bnano, the C-helix of CNBD increases in length, a behavior previously observed in
the case of cAMP binding (Puljung and Zagotta, 2013). This portion of C-helix includes the two resi-
dues R662 and K665 engaged in salt bridge formation with respectively E250/D257 and E264 of TRIP8b-
nano. It is important to note that these two cationic residues are also involved in cAMP binding
(Zagotta et al., 2003; Zhou and Siegelbaum, 2007; Lolicato et al., 2011). The finding that TRIP8b
and cAMP share the same binding sites on the C-helix provides a solid molecular explanation for
Figure 5. Effects of TRIP8bnano on voltage-dependent activation of If and spontaneous rate in rabbit sinoatrial node (SAN) myocytes. (A) Representative
whole-cell If currents recorded, at the indicated voltages, in the control solution and in the presence of 10 mM TRIP8bnano, without (top) and with 1 mM
cAMP in the pipette (bottom). (B) Mean If activation curves were measured using a two-step protocol (see Materials and methods) in control (filled
circles) or in the presence of: 1 mM cAMP (open circles); 10 mM TRIP8bnano (filled squares); 1 mM cAMP +10 mM TRIP8bnano (open squares). Ligands were
added in the patch pipette. Half activation potential (V1/2) of If activation curves measured in control =  64.1 ± 0.4 mV or in the presence of: 1 mM
cAMP =  59.9 ± 0.4 mV; 10 mM TRIP8bnano =  67.7 ± 0.4 mV; 1 mM cAMP +10 mM TRIP8bnano =  67.6 ± 0.7 mV. Data are presented as mean ± SEM.
Number of cells (N) was 15. V1/2 values are significantly different between each other’s whit the exception of V1/2 obtained in the presence TRIP8bnano
and cAMP +TRIP8 bnano. Statistical analysis performed with two-way ANOVA, followed by post-hoc Bonferroni test (*p<0.05) (C) (Left) Representative
recordings of single SAN cell spontaneous activity in control and in the presence of 10 mM TRIP8bnano. (Right) Mean spontaneous rate (Hz) recorded in
control solution = 3.65 ± 0.29 Hz and in the presence of 10 mM TRIP8bnano added to the pipette = 2.69 ± 0.27 Hz. Data are presented as mean ± SEM.
Number of cells (N) was 7. Statistical analysis performed with t test (*p<0.05).
DOI: https://doi.org/10.7554/eLife.35753.016
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Figure 6. Effect of TRIP8bnano and TAT-TRIP8bnano on If and ICa,L in mouse sinoatrial node (SAN) myocytes. (A) Representative examples of If recordings
at  95 mV in control conditions (top), in 10 mM TRIP8bnano dialyzed cell (middle) and in cells perfused with 10 mM TAT-TRIP8bnano (bottom), before
(black trace) and after (red trace) application of ISO 100 nM. The voltage-clamp protocol used for recordings is shown above current traces. (B) Mean
normalized If current density recorded at  95 mV in absence and in presence of 10 mM TRIP8bnano in the patch pipette, before (open bars) and after
Figure 6 continued on next page
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functional data, which imply a competition between the two regulators (Han et al., 2011;
DeBerg et al., 2015; Bankston et al., 2017). Another study, however, has indicated that a direct
competition model cannot fully explain the mutually antagonistic effect of the two ligands (Hu et al.,
2013). Specifically, the fact that the inhibitory effect of TRIP8b on channel activity persists even at
saturating cAMP concentrations advocated an allosteric component in the regulation mechanism.
Our data, showing that the N547D mutation in the N-bundle loop controls cAMP affinity in the bind-
ing pocket support the conclusion that the N-bundle loop allosterically controls cAMP binding. This
is not surprising, given its crucial role of mechanically transducing to the pore the cAMP binding
event within the CNBD (Saponaro et al., 2014).
The structural model also explains why a previously identified peptide selected by Lyman et al.
(2017) failed to reproduce the binding affinity of the TRIP8bcore for the CNBD. This 37 aa long frag-
ment is lacking one important contact residue, namely E240, which, in our model, forms a salt bridge
with R650 of the CNBD. The loss of one crucial interaction is presumably the reason for the major
decrease in affinity (about 20 times lower) reported for this peptide.
TRIP8bnano as a tool for modulating native If currents
In functional assays, we showed that TRIP8bnano binds the HCN channel CNBD with high affinity and
fully abolishes the cAMP effect in all tested isoforms (HCN1, 2 and 4).
Given the small size of the peptide (<5 kDa), TRIP8bnano is a good candidate for in vivo delivery
into intact cells. As a proof of concept, we fused TRIP8bnano to an internalization sequence, the TAT
peptide (YGRKKRRQRRRGG). This arginine-rich Cell Penetrating Peptide (CPP) from HIV has been
used in several studies as a vehicle for the delivery of large molecules across the plasma membrane
(Guidotti et al., 2017). In our case, the challenge was to construct a TAT-fusion protein, which
would be efficiently delivered in the cell without compromising TRIP8bnano function. Indeed, covalent
conjugation of a CPP may negatively affect both the function of the cargo, and the cell-penetrating
efficacy of the CPP-peptide chimera (Kristensen et al., 2016). The design of the construct was
greatly supported by the detailed knowledge of the electrostatic interactions with the target protein
CNBD, provided by the NMR model structure. This structure suggested that the polycationic TAT
sequence would be best linked to the N-terminus of TRIP8bnano to avoid interference with the cat-
ionic residues of CNBD, mainly located in the distal region of C-helix, which are crucial for the bind-
ing of the peptide. From test experiments with the TAT-TRIP8bnano peptide in SAN myocytes, we
can conclude that this strategy was successful in that: (i) the peptide is efficiently delivered inside the
cells; (ii) it is kept in its active conformation; (iii) the TAT sequence did not damage cell membranes
and did not interfere with the basic features of If and ICa,L currents; (iv) the modification did not
affect the proteolytic stability of the TRIP8bnano peptide at least in the time frame of our experi-
ments (30 min to 1 hr).
Figure 6 continued
(filled bars) 100 nM ISO perfusion. Data are presented as mean ± SEM. Number of cells (N)  6. Statistical analysis performed with two-way ANOVA
test, followed by Sidak multiple comparisons test (**p<0.01). (C) Mean normalised If current density recorded at  95 mV in control solution or in the
solution containing 10 mM TAT-TRIP8bnano, in absence (open bars) and in the presence (filled bars) of 100 nM ISO. Data are presented as mean ± SEM.
Number of cells (N)  8. Statistical analysis performed with two-way ANOVA test, followed by Sidak multiple comparisons test (****p<0.0001). (D)
Representative examples of ICa,L recordings at  10 mV in control conditions (top), in 10 mM TRIP8bnano dialyzed cell (middle) and in cells perfused with
10 mM TAT-TRIP8bnano (bottom), before (black trace) and after (red trace) application of ISO 100 nM. The voltage-clamp protocol used for recordings is
shown above current traces. (E) Mean normalized ICa,L current density recorded at  10 mV in absence and in presence of 10 mM TRIP8bnano in the patch
pipette, before (open bars) and after (filled bars) 100 nM ISO perfusion. Data are presented as mean ± SEM. Number of cells (N)  8. Statistical analysis
performed with two-way ANOVA test, followed by Sidak multiple comparisons test (***p<0.001; ****p<0.0001). (F) Mean normalized ICa,L current
density recorded at  10 mV in control solution or in the solution containing 10 mM TAT-TRIP8bnano, in absence (open bars) and in the presence (filled
bars) of 100 nM ISO. Data are presented as mean ± SEM. Number of cells (N)  7. Statistical analysis performed with two-way ANOVA test, followed by
Sidak multiple comparison test (**p<0.01; ***p<0.001).
DOI: https://doi.org/10.7554/eLife.35753.017
The following figure supplement is available for figure 6:
Figure supplement 1. Effect of TAT- (SCRAMBLED) TRIP8bnano on If in mouse sinoatrial node (SAN) myocytes.
DOI: https://doi.org/10.7554/eLife.35753.018
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In conclusion, we successfully used the miniaturized TRIP8bnano peptide to selectively control
native If currents and the rate of spontaneous firing in SAN myocytes. Unlike channel blockers, which
inhibit ionic currents, the peptide only interferes with the cAMP-based regulation of HCN channels,
while leaving basal HCN functions unaltered. In addition and in contrast to even the most selective
blockers, it is selective for HCN and it does not interfere with other cAMP-modulated channels pres-
ent in the SAN, such as L-type Ca2+ channels. Collectively, this makes TRIP8bnano a promising tool in
targeted therapeutic interventions.
Materials and methods
Key resources table
Reagent type
species Designation Source or reference Identifiers Additional information
Gene (human) HCN1 Xention Ltd.
(Cambridge, UK)
NM_021072.3
Gene (mouse) HCN2 PMID: 11331358 NM_008226.2 Laboratory of Steven A.
Siegelbaum
Gene (rabbit) HCN4 PMID: 10212270 NM_001082707.1
Gene (mouse) TRIP8b PMID: 19555649 Laboratory of Steven A.
Siegelbaum
Strain, strain
background (E. coli)
DH5a Thermo Fisher Scientific
Strain, strain
background (E. coli)
Stbl2 Thermo Fisher Scientific
Strain, strain
background (Mus
musculus)
Male or female
C57BL/6J mice
The Jackson Laboratory RRID:MGI:5653012
Strain, strain
background (Oryctolagus
cuniculus)
New Zealand white female
rabbits
Envigo ID strain:HsdOkd:NZW
Cell line (human) HEK 293T ATCC RRID:CVCL_0063 Tested negative for
mycoplasma
Biological sample
(Mus musculus)
Isolated adult Sinoatrial node
(SAN) cardiomyocytes
PMID: 11557233
Biological sample
(Oryctolagus cuniculus)
Isolated adult Sinoatrial node
(SAN) cardiomyocytes
PMID: 2432247
Recombinant DNA
reagent
pET-52b (plasmid) EMD Millipore
Recombinant DNA
reagent
modified pET-24b (plasmid) Laboratory of Daniel L.
Minor, Jr.
Recombinant DNA
reagent
pcDNA 3.1 (plasmid) Clontech Laboratories
Recombinant DNA
reagent
pCI (plasmid) Promega
Recombinant DNA
reagent
TRIP8bnano (cDNA) This paper Made by PCR and
cloning; see Constructs
Recombinant DNA
reagent
TRIP8bnano (E240R) (cDNA) This paper Made by site-directed
mutagenesis of TRIP8bnano
wt; see Constructs
Recombinant DNA
reagent
TRIP8bnano (E241R) (cDNA) This paper Made by site-directed
mutagenesis of TRIP8bnano
wt; see Constructs
Recombinant DNA
reagent
TRIP8bnano (E264K) (cDNA) This paper Made by site-directed
mutagenesis of TRIP8bnano
wt; see Constructs
Continued on next page
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Continued
Reagent type
species Designation Source or reference Identifiers Additional information
Recombinant DNA
reagent
TRIP8bnano (E265K) (cDNA) This paper Made by site-directed
mutagenesis of TRIP8bnano
wt; see Constructs
Recombinant DNA
reagent
TRIP8bnano (D252N) (cDNA) This paper Made by site-directed
mutagenesis of TRIP8bnano
wt; see Constructs
Recombinant DNA
reagent
TRIP8bcore (cDNA) PMID: 25197093
Recombinant DNA
reagent
human HCN2 CNBD (cDNA) PMID: 25197093
Recombinant DNA
reagent
human HCN2 CNBD (N547D)
(cDNA)
This paper Made by site-directed
mutagenesis of human HCN2
CNBD wt; see Constructs
Recombinant DNA
reagent
human HCN2 CNBD (K665E)
(cDNA)
This paper Made by site-directed
mutagenesis of human HCN2
CNBD wt; see Constructs
Recombinant DNA
reagent
human HCN2 CNBD (K666E)
(cDNA)
This paper Made by site-directed
mutagenesis of human HCN2
CNBD wt; see Constructs
Recombinant DNA
reagent
human HCN2 CNBD (R650E)
(cDNA)
This paper Made by site-directed
mutagenesis of human HCN2
CNBD wt; see Constructs
Recombinant DNA
reagent
human HCN1 (cDNA) Xention Ltd.
(Cambridge, UK)
Recombinant DNA
reagent
TRIP8b (1a4) (cDNA) This paper Made by PCR and cloning;
see Constructs
Recombinant DNA
reagent
mouse HCN2 (cDNA) Laboratory of Steven A.
Siegelbaum
Recombinant DNA
reagent
rabbit HCN4 (cDNA) PMID: 10212270
Recombinant DNA
reagent
mouse HCN2 (N520D) (cDNA) This paper Made by site-directed
mutagenesis of mouse
HCN2 wt; see Constructs
Sequence-based
reagent
human HCN1 (R549E) (cDNA) This paper Made by site-directed
mutagenesis of human
HCN1 wt; see Constructs
Peptide, recombinant
protein
TAT-TRIP8bnano (YGRKKRRQRRRGG-
NHSLEEEFERAKAAVESTEFWDKMQA
EWEEMARRNWISEN)
CASLO ApS
Peptide, recombinant
protein
TAT-(SCRAMBLED)TRIP8bnano
(YGRKKRRQRRRGG-RNEAEAAE
VAQKDMINERARTHEFEWESWE
MWENLSESFK)
CASLO ApS
Commercial assay
or kit
QuickChange Lightning Site-
Directed Mutagenesis Kit
Agilent
Commercial assay
or kit
Thermo Scientific TurboFect
Transfection Reagent
Thermo Fisher Scientific
Chemical compound,
drug
Adenosine 3’, 5’-cyclic
monophosphate (cAMP)
SIGMA
Software, algorithm Clampfit 10.5/10.7 Molecular Devices RRID:SCR_011323
Software, algorithm CYANA-2.1 L. A. Systems, Inc.
Software, algorithm AMBER 12.0 http://pyenmr.cerm.unifi.it/
access/index/amps-nmr
Software, algorithm HADDOCK2.2 www.wenmr.eu
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Constructs
The cDNA fragment encoding residues 235–275 (TRIP8bnano) of mouse TRIP8b (splice variant 1a4)
was cloned into pET-52b (EMD Millipore) downstream of a Strep (II) tag sequence, while the cDNA
fragment encoding residues 521–672 of human HCN2 (HCN2 CNBD) was cloned, in a previous
study, into a modified pET-24b downstream of a double His6-maltose-binding protein (MBP)
(Saponaro et al., 2014). The cDNA encoding full-length human HCN1 channel and mouse TRIP8b
(1a4) were cloned into the mammalian expression vector pcDNA 3.1 (Clontech Laboratories), while
mouse HCN2 channel and rabbit HCN4 channel were cloned into the mammalian expression vector
pCI (Promega). Mutations were generated by site-directed mutagenesis (QuikChange site-directed
mutagenesis kit; Agilent Technologies) and confirmed by sequencing.
Preparation of proteins
The HCN2 CNBD WT and mutant proteins, as well as the TRIP8bcore and TRIP8bnano proteins (WT
and mutants) were produced and purified following the procedure previously described
(Saponaro et al., 2014).
Structure calculation of the cAMP-free human HCN2 CNBD in complex
with TRIP8bnano and vice versa
NMR experiments were acquired on Bruker Avance III 950, 700 and 500 MHz NMR spectrometers
equipped with a TXI-cryoprobe at 298 K. The acquired triple resonance NMR experiments for the
assignment of backbone resonances of cAMP-free HCN2 CNBD (CNBD hereafter) in complex with
TRIP8bnano and vice versa are summarized in Figure 3-source data 1.
15N, 13C’, 13Ca,
13Cb, and Ha
chemical shifts were used to derive f and y dihedral angles by TALOS + program (Cornilescu et al.,
1999) for both CNBD and TRIP8bnano. For TRIP8bnano, CYANA-2.1 structure calculation
(Gu¨ntert and Buchner, 2015) was performed using 68 f and y dihedral angles and 40 backbone
hydrogen bonds as input. For CNBD, CYANA-2.1 structure calculation was performed using 108 f
and y dihedral angles, combined with the NOEs obtained in our previous determination of the
cAMP-free form of the CNBD (Saponaro et al., 2014) for those regions not affected by the interac-
tion with TRIP8bnano. The 10 conformers of TRIP8bnano and CNBD with the lowest residual target
function values were subjected to restrained energy minimization with AMBER 12.0 (Case, 2012)
(http://pyenmr.cerm.unifi.it/access/index/amps-nmr) and used as input in docking calculations.
Docking calculations
Docking calculations were performed with HADDOCK2.2 implemented in the WeNMR/West-Life
GRID-enabled web portal (www.wenmr.eu). The docking calculations are driven by ambiguous inter-
action restraints (AIRs) between all residues involved in the intermolecular interactions
(Dominguez et al., 2003). Active residues of the CNBD were defined as the surface exposed resi-
dues (at least 50% of solvent accessibility), which show chemical shift perturbation upon TRIP8bnano
binding.
The assignment of the CNBD bound to TRIP8bnano allowed to highlight the residues of CNBD
whose backbone featured appreciable Combined Chemical Shift Perturbation (CSP) (Figure 3—fig-
ure supplement 1). The combined CSP (DHN) is given by the equation DHN={((HNfree HNbound)
2+((-
Nfree Nbound)/5)
2)/2}½ (Garrett et al., 1997).
Passive residues of CNBD were defined as the residues close in space to active residues and with
at least 50% solvent accessibility.
In the case of TRIP8bnano, the conserved stretch E239-E243, located in helix N, was defined as
active region in a first docking calculation, while all the other solvent accessible residues of the pep-
tide were defined as passive. This docking calculation generated several clusters. A post-docking fil-
ter step allowed us to select those clusters having an orientation of TRIP8bnano bound to CNBD in
agreement with a DEER study on the CNBD - TRIP8bnano interaction (DeBerg et al., 2015). The
selected clusters grouped in two classes on the basis of the orientation of helix N of TRIP8bnano (N)
relative to CNBD (Figure 3—figure supplement 2. A second docking calculation was subsequently
performed introducing also residues E264-E265, located in helix C of TRIP8bnano as active residues.
The active residues for CNBD were the same used for the first calculation. For this second HAD-
DOCK calculation, 14 clusters were obtained and ranked according to their HADDOCK score.
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Among them only four clusters showed both an orientation of TRIP8bnano bound to CNBD in agree-
ment with the DEER study (DeBerg et al., 2015) and the involvement of E239-E243 stretch of TRIP8b-
nano in the binding to CNBD. These clusters were manually analyzed and subjected to a per-cluster
re-analysis following the protocol reported in http://www.bonvinlab.org/software/haddock2.2/analy-
sis/#reanal. From this analysis, it resulted that the top-ranking cluster, i.e. the one with the best ener-
getic and scoring functions, has a conformation in agreement with mutagenesis experiments
(Figure 3—figure supplement 3). Energy parameters (van der Waals energy, electrostatic energy,
desolvation energy, and the penalty energy due to violation of restraints) for this complex model are
reported in Figure 3—source data 2.
Both docking calculations were performed using 10 NMR conformers of both the CNBD and the
TRIP8bnano structures calculated as described above. In the TRIP8bnano structures the unfolded N-
and C-terminal regions were removed, while in the CNBD structures only the unfolded N-terminal
region was removed. This is because the C-terminal region of the CNBD is known to comprise resi-
dues involved in TRIP8bnano binding (Saponaro et al., 2014). Flexible regions of the proteins were
defined based on the active and passive residues plus two preceding and following residues. The
residue solvent accessibility was calculated with the program NACCESS (Hubbard and Hornton,
1993). In the initial rigid body docking calculation phase, 5000 structures of the complex were gen-
erated, and the best 400 in terms of total intermolecular energy were further submitted to the semi-
flexible simulated annealing and a final refinement in water. Random removal of the restraints was
turned off. The number of flexible refinement steps was increased from the default value of 500/
500/1000/1000 to 2000/2000/2000/4000. The final 400 structures were then clustered using a cutoff
of 5.0 A˚ of RMSD to take into consideration the smaller size of protein-peptide interface.
Electrophysiology of HEK 293 T cells
HEK 293 T cells were cultured in Dulbecco’s modified Eagle’s medium (Euroclone) supplemented
with 10% fetal bovine serum (Euroclone), 1% Pen Strep (100 U/mL of penicillin and 100 mg/ml of
streptomycin), and stored in a 37˚C humidified incubator with 5% CO2. The plasmid containing
cDNA of wild-type and mutant HCN1, HCN2 and HCN4 channels (1 mg) was co-transfected for tran-
sient expression into HEK 293 T cells with a plasmid containing cDNA of Green Fluorescent Protein
(GFP) (1.3 mg). For co-expression with TRIP8b (1a-4), HEK 293 T cells were transiently transfected
with wild-type (wt) and/or mutant human HCN1 cDNA (1 mg), wt TRIP8b (1a-4) cDNA (1 mg) and
cDNA of Green Fluorescent Protein (GFP) (0.3 mg).
One day after transfection, GFP-expressing cells were selected for patch-clamp experiments in
whole-cell configuration. The experiments were conducted at R.T. The pipette solution in whole cell
experiments contained: 10 mM NaCl, 130 mM KCl, 1 mM egtazic acid (EGTA), 0.5 mM MgCl2, 2
mM ATP (Mg salt) and 5 mM HEPES–KOH buffer (pH 7.4). The extracellular bath solution contained
110 mM NaCl, 30 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2 and 5 mM HEPES–KOH buffer (pH 7.4).
TRIP8bnano was added (10 mM) to the pipette solution. cAMP was added at different concentra-
tion to the pipette solution depending on the HCN isoform used: 0 mM for HCN1, 5 mM for HCN2
and 1 mM for HCN4.
Whole-cell measurements of HCN channels were performed using the following voltage clamp
protocol depending on the HCN isoform measured: for HCN1, holding potential was –30 mV (1 s),
with steps from –20 mV to –120 mV (10 mV interval, 3.5 s) and tail currents recorded at –40 mV (3 s);
for HCN2, holding potential was –30 mV (1 s), with steps from –40 mV to –130 mV (10 mV interval, 5
s) and tail currents recorded at  40 mV (5 s); for HCN4, holding potential was –30 mV (1 s), steps
from –30 mV to –165 mV (15 mV interval, 4.5 s) and tail currents were recorded at  40 mV (5 s). Cur-
rent voltage relations and activation curves were obtained by the above activation and deactivation
protocols and analyzed by the Boltzmann equation, see data analysis.
Isolation and electrophysiology of rabbit sinoatrial node cells
Animal protocols conformed to the guidelines of the care and use of laboratory animals established
by Italian and European Directives (D. Lgs n˚ 2014/26, 2010/63/UE). New Zealand white female rab-
bits (0.8–1.2 kg) were anesthetized (xylazine 5 mg/Kg, i.m.), and euthanized with an overdose of
sodium thiopental (i.v.); hearts were quickly removed, and the SAN region was isolated and cut in
small pieces. Single SAN cardiomyocytes were isolated following an enzymatic and mechanical
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procedure as previously described (DiFrancesco et al., 1986). Following isolation, cells were main-
tained at 4˚C in Tyrode solution: 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5.5 mM
D-glucose, 5 mM HEPES-NaOH (pH 7.4).
For patch clamp experiments cells were placed in a chamber on an inverted microscope and
experiments were performed in the whole-cell configuration at 35 ± 0.5˚C. The pipette solution con-
tained: 10 mM NaCl, 130 mM KCl, 1 mM egtazic acid (EGTA), 0.5 mM MgCl2, and 5 mM HEPES–
KOH buffer (pH 7.2). The If current was recorded from single cells superfused with Tyrode solution
with 1 mM BaCl2, and 2 mM MnCl2.
If activation curves were obtained using a two-step protocol in which test voltage steps (from  30
to  120 mV, 15 mV interval) were applied from a holding potential of  30 mV and were followed by
a step to  125 mV. Test steps had variable durations so as to reach steady –state activation at all
voltages. Analysis was performed with the Boltzmann equation (see data analysis).
In current-clamp studies, spontaneous action potentials were recorded from single cells super-
fused with Tyrode solution, and rate was measured from the interval between successive action
potential. When indicated cAMP (1 mM) and/or nanoTRIP8b (10 mM) were added to the pipette
solution.
Isolation and electrophysiology of mouse sinoatrial node cells
Mice were killed by cervical dislocation under general anesthesia consisting of 0.01 mg/g xylazine
(2% Rompun; Bayer AG), 0.1 mg/g ketamine (Imalge`ne; Merial) and 0.04 mg/g of Na-pentobarbital
(Euthanasol VET, Laboratoire TVM, Lempdes, France), and beating hearts were quickly removed.
The SAN region was excised in warmed (35˚C) Tyrode’s solution containing: 140 mM NaCl, 5.4 mM
KCl, 1.8 mM CaCl2, 1 mM MgCl2, 1 mM Hepes-NaOH (pH = 7.4), and 5.5 mM D-glucose and cut in
strips. Strips were then transferred into a ‘low-Ca2+-low-Mg2+’ solution containing: 140 mM NaCl;
5.4 mM KCl, 0.5 mM MgCl2, 0.2 mM CaCl2, 1.2 mM KH2PO4, 50 mM taurine, 5.5 mM D-glucose, 1
mg/ml bovine serum albumin (BSA), 5 mM Hepes-NaOH (pH = 6.9).
Tissue was digested by adding Liberase TH (0.15 mg/ml, Roche Diagnostics GmbH, Mannheim,
Germany), elastase (1.9 U/ml, Worthington, Lakewood). Digestion was carried out for a variable time
of 15–18 min at 35˚C. Tissue strips were then washed and transferred into a modified ‘Kraftbru¨he’
(KB) medium containing: 70 mM L-glutamic acid, 20 mM KCl, 80 mM KOH, (±) 10 mM D- b-OH-
butyric acid; 10 mM KH2PO4, 10 mM taurine, 1 mg/ml BSA and 10 mM Hepes-KOH (pH = 7.4).
Single SAN cells were isolated by manual agitation in KB solution at 35˚C for 30–50 s.
Cellular automaticity was recovered by re-adapting the cells to a physiological extracellular Ca2+
concentration by addition of a solution containing: 10 mM NaCl, 1.8 mM CaCl2 and normal Tyrode
solution containing BSA (1 mg/ml). The final storage solution contained: 100 mM NaCl, 35 mM KCl,
1.3 mM CaCl2, 0.7 mM MgCl2, 14 mM L-glutamic acid, (±) 2 mM D-b-OH-butyric acid, 2 mM
KH2PO4, 2 mM taurine, 1 mg/ml BSA, (pH = 7.4). Cells were then stored at room temperature until
use. All chemicals were from SIGMA (St Quentin Fallavier, France).
For electrophysiological recording, SAN cells in the storage solution were harvested in special
custom-made recording plexiglas chambers with glass bottoms for proper cell attachment and
mounted on the stage of an inverted microscope (Olympus IX71) and perfused with normal Tyrode
solution. The recording temperature was 36˚C. We used the whole-cell variation of the patch-clamp
technique to record cellular ionic currents, by employing a Multiclamp 700B (Axon Instruments Inc.,
Foster USA) patch clamp amplifier. Recording electrodes were fabricated from borosilicate glass, by
employing a WZ DMZ-Universal microelectrode puller (Zeitz-Instruments Vertriebs GmbH, Mar-
tinsried, Germany).
If was recorded under standard whole-cell configuration during perfusion of standard Tyrode’s
containing 2 mM BaCl2 to block IK1. Patch-clamp pipettes were filled with an intracellular solution
containing: 130 mM KCl, 10 mM NaCl, 1 mM EGTA, 0.5 mM MgCl2 and 5 mM HEPES (pH 7.2).
For recording of L-type Ca2+ currents, pipette solution contained: 125 mM CsOH, 20 mM tetrae-
thylammonium chloride (TEA-Cl), 1.2 mM CaCl2, 5 mM Mg-ATP, 0.1 mM Li2-GTP, 5 mM EGTA and
10 mM HEPES (pH 7.2 with aspartate). 30 mM TTX (Latoxan, Portes le`s Valence, France) to block INa
was added to external solution containing: 135 mM tetraethylammonium chloride (TEA-Cl), 4 mM
CaCl2,10 mM 4-amino-pyridine, 1 mM MgCl2, 10 mM HEPES and 1 mg/ml Glucose (pH 7.4 with
TEA-OH).
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Electrodes had a resistance of about 3 MW. Seal resistances were in the range of 2–5 GW. 10 mM
TRIPb8nano was added to pipette solution. 10 mM TAT-TRIPb8nano was added in cell storage solution
for at least 30 min before patch clamp recording.
TAT-peptides
TAT-TRIP8bnano (YGRKKRRQRRRGG-NHSLEEEFERAKAAVESTEFWDKMQAEWEEMARRNWISEN,
TAT sequence is shown in bold type) and TAT-(SCRAMBLED)TRIP8bnano (YGRKKRRQRRRGG-
RNEAEAAEVAQKDMINERARTHEFEWESWEMWENLSESFK, TAT sequence is shown in bold type)
were purchased from CASLO ApS. TAT-peptides were dissolved in Milliq water (1.5 mM) and added
to the petri dish at the final concentration (10 mM) 30 min before current recordings. During the
patch clamp experiments, cells were perfused with standard Tyrode with 2 mM BaCl2 (see above)
without the peptides. Recordings from the same petri dish were performed over a time window of
10 to 60 min in peptide-free solution
Data analysis
Data were acquired at 1 kHz using an Axopatch 200B amplifier and pClamp10.5 or 10.7 software
(Axon Instruments). Data were analyzed off-line using Clampfit 10.5 or 10.7 (Molecular Devices) and
Origin 2015 or 16 (OriginLab Corp., Northampton MA). Activation curves were analyzed by the
Boltzmann equation, y = 1/{1 + exp[(V V1/2)/s]}, where y is fractional activation, V is voltage, V1/2
half-activation voltage, and s the inverse slope factor (mV) (DiFrancesco, 1999). Mean activation
curves were obtained by fitting individual curves from each cell to the Boltzmann equation and then
averaging all curves obtained. Activation time constants (ton) were obtained by fitting a single expo-
nential function,
I=I0 exp(-t/t) to current traces recorded at the indicated voltages.
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